Can-fite biopharma ltd. (CANF)
CashFlow / Yearly
Dec'17Dec'16Dec'15
Cash flows from operating activities:
Loss

-6,433

-8,393

-6,509

Adjustments to reconcile loss to net cash used:
Depreciation of property, plant and equipment

19

18

16

Share-based payment

192

309

109

Change in fair value of long-term investment

5

-

-

Decrease in severance pay, net

-

-152

5

Changes in fair value of warrants liability exercisable into shares

-72

-232

80

Gain from sale of investment in previously consolidated subsidiaries (a)

-769

-

-

Exchange differences on balances of cash and cash equivalents

83

82

13

Adjustments to reconcile net loss

-542

25

223

Working capital adjustments:
Increase in accounts receivable and prepaid expenses and lease deposit

-2,907

1,397

332

Increase (decrease) in trade payables

-293

816

187

Increase (decrease) in deferred revenues

-289

335

1,130

Decrease in other accounts payable

906

-100

-178

Adjustments to working capital

-1,997

-346

1,471

Net cash used in operating activities

-8,972

-8,714

-4,815

Cash flows from investing activities:
Purchase of property, plant and equipment

7

10

42

Proceeds from sale of investments in previously consolidated subsidiaries (a)

-22

0

0

Net cash used in investing activities

-29

-10

-42

Cash flows from financing activities:
Issuance of share capital and warrants, net of issuance expenses

4,474

0

12,511

Net cash provided by financing activities

4,474

0

12,511

Exchange differences on balances of cash and cash equivalents

-83

-82

-13

Increase in cash and cash equivalents

-4,610

-8,806

7,641

Supplemental disclosure of cash flow information:
Cash paid during the year for income taxes

29

29

5

Cash received during the year for interest, net

69

89

22